If you have chronic Hepatitis B, there is a direct, specific question you should bring to your next doctor's appointment: Have I ever been tested for Hepatitis Delta Virus?
For years, the honest clinical answer to why that test was often skipped was straightforward: there was nothing to do with a positive result. That has changed. On May 22, 2026, the FDA approved bulevirtide-gmod (Hepcludex; Gilead Sciences) as the first-ever treatment for chronic Hepatitis Delta Virus (HDV) infection in the United States — and that single regulatory decision has shifted the clinical calculus for testing an estimated 80,000 Americans who may be living with this dangerous, undiagnosed co-infection right now.
